Trial NCT04412538
Publication Che Y,Clin Infect Dis,2020
Primary outcome on the report: Seroconversion rates of the anti-SARS-CoV-2 neutralizing antibody and ELISA IgG antibody at days 14 (0, 14 procedure) and 28 (0, 28 procedure), respectively, after the boost immunization